pentamidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2090	100-33-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pentamidine isetionate pentamidine diisethionate pentamidine pentamidine isethionate pentamidin pentamidine mesylate pentamidine mesilate	Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. Molecular weight: 340.43 Formula: C19H24N4O2 CLOGP: 2.31 LIPINSKI: 0 HAC: 6 HDO: 4 TPSA: 118.20 ALOGS: -4.16 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pentamidine isetionate
pentamidine diisethionate
pentamidine
pentamidine isethionate
pentamidin
pentamidine mesylate
pentamidine mesilate

Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.

Molecular weight: 340.43
Formula: C19H24N4O2
CLOGP: 2.31
LIPINSKI: 0
HAC: 6
HDO: 4
TPSA: 118.20
ALOGS: -4.16
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.28	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	100 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	12 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	11.75 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	53 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	74 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.09 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	25 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 16, 1984	FDA	FRESENIUS KABI USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aplastic anaemia	162.39	24.07	51	5210	9518	63474243
Febrile neutropenia	147.42	24.07	102	5159	118347	63365414
Pneumocystis jirovecii pneumonia	126.78	24.07	49	5212	16865	63466896
Toxoplasmosis	123.46	24.07	28	5233	1495	63482266
Nocardiosis	81.14	24.07	21	5240	1955	63481806
Antinuclear antibody negative	71.64	24.07	13	5248	221	63483540
Hypoalbuminaemia	66.97	24.07	28	5233	11777	63471984
Coombs positive haemolytic anaemia	65.66	24.07	13	5248	358	63483403
Cytomegalovirus viraemia	63.22	24.07	22	5239	5627	63478134
Antithrombin III	62.49	24.07	11	5250	156	63483605
Neutropenia	59.81	24.07	73	5188	174932	63308829
Delayed graft function	56.68	24.07	14	5247	1079	63482682
Cytokine release syndrome	55.52	24.07	26	5235	14288	63469473
Pulmonary mucormycosis	54.91	24.07	11	5250	322	63483439
Herpes simplex reactivation	54.55	24.07	12	5249	556	63483205
Lymphopenia	49.42	24.07	26	5235	18301	63465460
Gastritis haemorrhagic	47.21	24.07	13	5248	1532	63482229
Pancytopenia	46.00	24.07	48	5213	96885	63386876
Antiphospholipid syndrome	45.32	24.07	13	5248	1777	63481984
Graft versus host disease	45.04	24.07	18	5243	6745	63477016
Complex regional pain syndrome	41.79	24.07	13	5248	2344	63481417
Systemic mycosis	40.91	24.07	11	5250	1186	63482575
Focal myositis	40.74	24.07	6	5255	24	63483737
Thrombotic microangiopathy	40.39	24.07	19	5242	10542	63473219
Haemophagocytic lymphohistiocytosis	40.27	24.07	19	5242	10608	63473153
Rhodococcus infection	38.74	24.07	7	5254	116	63483645
Pyrexia	38.44	24.07	105	5156	470373	63013388
Mycobacterium avium complex infection	38.34	24.07	13	5248	3075	63480686
Leukopenia	37.96	24.07	39	5222	77251	63406510
Cryptosporidiosis infection	37.73	24.07	8	5253	311	63483450
Acute kidney injury	37.21	24.07	73	5188	263342	63220419
Enterococcal infection	35.92	24.07	16	5245	7832	63475929
Cytopenia	35.73	24.07	18	5243	11583	63472178
Cytomegalovirus infection	35.64	24.07	22	5239	20930	63462831
Plasma cell myeloma	35.58	24.07	27	5234	35878	63447883
Escherichia bacteraemia	35.42	24.07	13	5248	3870	63479891
Mucormycosis	35.30	24.07	12	5249	2859	63480902
Anxiety disorder	34.89	24.07	13	5248	4037	63479724
Multiple organ dysfunction syndrome	34.14	24.07	32	5229	56720	63427041
Immune effector cell-associated neurotoxicity syndrome	33.92	24.07	11	5250	2266	63481495
Encephalitis cytomegalovirus	33.24	24.07	8	5253	553	63483208
Renal tubular necrosis	32.44	24.07	17	5244	11861	63471900
Pain	31.71	24.07	11	5250	740617	62743144
Respiratory failure	30.77	24.07	40	5221	101818	63381943
Thrombocytopenia	30.49	24.07	49	5212	151108	63332653
Ectropion	29.81	24.07	6	5255	180	63483581
Erysipelas	29.54	24.07	14	5247	7891	63475870
Cytomegalovirus gastroenteritis	29.08	24.07	6	5255	204	63483557
Cytomegalovirus infection reactivation	27.97	24.07	11	5250	3952	63479809
Acute respiratory failure	27.86	24.07	23	5238	34462	63449299
Blood phosphorus decreased	26.72	24.07	11	5250	4442	63479319
Pleuritic pain	26.32	24.07	13	5248	8016	63475745
Bone marrow failure	24.64	24.07	20	5241	29270	63454491
Brain oedema	24.38	24.07	15	5246	14180	63469581
Malacoplakia	24.09	24.07	5	5256	175	63483586

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nocardiosis	169.68	20.19	53	7102	3898	34945878
Aplastic anaemia	110.16	20.19	49	7106	9667	34940109
Toxoplasmosis	102.35	20.19	28	7127	1288	34948488
Mucosal inflammation	97.48	20.19	73	7082	38549	34911227
Febrile bone marrow aplasia	94.98	20.19	42	7113	8167	34941609
Cerebral toxoplasmosis	94.92	20.19	28	7127	1693	34948083
Pneumocystis jirovecii pneumonia	62.90	20.19	43	7112	19667	34930109
Febrile neutropenia	62.17	20.19	105	7050	136744	34813032
Respiratory failure	61.27	20.19	92	7063	108480	34841296
Troponin T increased	58.63	20.19	21	7134	2350	34947426
Stenotrophomonas infection	57.17	20.19	20	7135	2090	34947686
Pyrexia	56.13	20.19	172	6983	332841	34616935
Pulmonary nocardiosis	55.49	20.19	16	7139	892	34948884
Immune reconstitution inflammatory syndrome	53.57	20.19	29	7126	8730	34941046
Neutropenia	53.14	20.19	106	7049	156672	34793104
Cytokine release syndrome	52.73	20.19	41	7114	22836	34926940
Glomerulosclerosis	47.90	20.19	14	7141	819	34948957
Botulism	46.59	20.19	10	7145	161	34949615
Oesophagitis	44.85	20.19	30	7125	13231	34936545
Pancytopenia	41.81	20.19	72	7083	95085	34854691
N-terminal prohormone brain natriuretic peptide increased	41.73	20.19	17	7138	2698	34947078
Kidney fibrosis	41.40	20.19	16	7139	2212	34947564
Haematopoietic stem cell mobilisation	40.88	20.19	9	7146	164	34949612
Graft versus host disease	40.85	20.19	26	7129	10543	34939233
Cystitis haemorrhagic	35.27	20.19	19	7136	5660	34944116
Haemophagocytic lymphohistiocytosis	33.75	20.19	25	7130	12948	34936828
Aspergillus infection	32.75	20.19	24	7131	12230	34937546
Cytomegalovirus infection	30.64	20.19	32	7123	26103	34923673
Cytomegalovirus viraemia	30.52	20.19	19	7136	7411	34942365
Thyroid gland abscess	29.99	20.19	6	7149	67	34949709
Venoocclusive liver disease	29.31	20.19	19	7136	7947	34941829
Generalised oedema	28.06	20.19	22	7133	12386	34937390
Infectious thyroiditis	27.87	20.19	6	7149	98	34949678
Genitourinary tract infection	27.54	20.19	6	7149	104	34949672
Cardiac pacemaker evaluation	26.54	20.19	6	7149	124	34949652
Photodermatosis	26.04	20.19	8	7147	555	34949221
Death	25.99	20.19	26	7129	398023	34551753
Staphylococcal bacteraemia	25.91	20.19	18	7137	8434	34941342
Bacterial toxaemia	25.57	20.19	6	7149	147	34949629
Face oedema	25.15	20.19	20	7135	11496	34938280
Urogenital infection bacterial	24.98	20.19	5	7150	56	34949720
Lymphopenia	24.73	20.19	23	7132	16312	34933464
Mycobacterium fortuitum infection	24.50	20.19	6	7149	177	34949599
Bronchospasm	24.21	20.19	19	7136	10712	34939064
Purpura non-thrombocytopenic	23.63	20.19	5	7150	75	34949701
Stenotrophomonas bacteraemia	23.32	20.19	5	7150	80	34949696
Elbow synostosis	22.82	20.19	4	7151	20	34949756
Parvovirus B19 infection	22.76	20.19	8	7147	847	34948929
Respiratory syncytial virus infection	21.80	20.19	13	7142	4696	34945080
B-cell aplasia	21.69	20.19	5	7150	113	34949663
Enterovirus infection	21.65	20.19	8	7147	978	34948798
Herpes zoster	20.56	20.19	30	7125	34369	34915407
Pancreatitis acute	20.50	20.19	27	7128	28114	34921662
Central nervous system lesion	20.36	20.19	14	7141	6449	34943327
Multiple organ dysfunction syndrome	20.36	20.19	47	7108	76519	34873257
Tongue disorder	20.29	20.19	13	7142	5326	34944450
Pulmonary necrosis	20.22	20.19	6	7149	370	34949406

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aplastic anaemia	262.58	19.03	98	11255	17807	79715228
Nocardiosis	256.76	19.03	73	11280	5606	79727429
Toxoplasmosis	203.74	19.03	52	11301	2645	79730390
Febrile neutropenia	195.18	19.03	200	11153	230799	79502236
Pneumocystis jirovecii pneumonia	141.55	19.03	76	11277	32432	79700603
Respiratory failure	101.84	19.03	127	11226	180784	79552251
Neutropenia	100.98	19.03	161	11192	287549	79445486
Cerebral toxoplasmosis	100.63	19.03	29	11324	2333	79730702
Mucosal inflammation	99.62	19.03	84	11269	75496	79657539
Cytokine release syndrome	95.35	19.03	61	11292	35937	79697098
Febrile bone marrow aplasia	90.99	19.03	42	11311	12978	79720057
Pancytopenia	89.52	19.03	114	11239	165631	79567404
Cytomegalovirus viraemia	85.38	19.03	40	11313	12781	79720254
Pyrexia	85.33	19.03	250	11103	678459	79054576
Graft versus host disease	76.42	19.03	39	11314	14987	79718048
Haemophagocytic lymphohistiocytosis	65.35	19.03	40	11313	21797	79711238
Pulmonary nocardiosis	64.44	19.03	18	11335	1293	79731742
Cytomegalovirus infection	57.40	19.03	48	11305	42596	79690439
Delayed graft function	54.32	19.03	20	11333	3487	79729548
Troponin T increased	54.24	19.03	20	11333	3502	79729533
Multiple organ dysfunction syndrome	53.06	19.03	75	11278	120171	79612864
Enterococcal infection	52.87	19.03	31	11322	15629	79717406
Pain	48.26	19.03	20	11333	703782	79029253
Stenotrophomonas infection	45.76	19.03	18	11335	3755	79729280
Immune reconstitution inflammatory syndrome	45.67	19.03	27	11326	13814	79719221
Mycobacterium avium complex infection	45.66	19.03	19	11334	4581	79728454
Lymphopenia	44.47	19.03	36	11317	30521	79702514
Haematopoietic stem cell mobilisation	42.15	19.03	9	11344	207	79732828
Botulism	41.97	19.03	10	11343	381	79732654
Photodermatosis	41.79	19.03	12	11341	952	79732083
Oesophagitis	40.48	19.03	31	11322	24258	79708777
Glomerulosclerosis	40.00	19.03	12	11341	1110	79731925
Staphylococcal bacteraemia	38.14	19.03	23	11330	12195	79720840
Focal myositis	37.49	19.03	6	11347	24	79733011
Venoocclusive liver disease	36.34	19.03	22	11331	11749	79721286
Cystitis haemorrhagic	35.90	19.03	20	11333	9152	79723883
Acute kidney injury	35.46	19.03	157	11196	519247	79213788
Thrombocytopenia	35.32	19.03	100	11253	265159	79467876
Pulmonary mucormycosis	35.31	19.03	11	11342	1154	79731881
N-terminal prohormone brain natriuretic peptide increased	35.29	19.03	16	11337	4739	79728296
Neutrophil count decreased	34.81	19.03	54	11299	93905	79639130
Mucormycosis	34.61	19.03	19	11334	8450	79724585
Thrombotic microangiopathy	34.18	19.03	26	11327	20143	79712892
Bone marrow failure	33.80	19.03	39	11314	51068	79681967
Hypoalbuminaemia	32.93	19.03	26	11327	21271	79711764
Optic neuritis	32.54	19.03	19	11334	9501	79723534
Immune effector cell-associated neurotoxicity syndrome	32.14	19.03	16	11337	5832	79727203
Cytopenia	31.76	19.03	25	11328	20358	79712677
Fall	31.57	19.03	15	11338	487614	79245421
Thyroid gland abscess	31.18	19.03	6	11347	80	79732955
Cryptosporidiosis infection	31.10	19.03	9	11344	734	79732301
Brain oedema	31.05	19.03	27	11326	25236	79707799
Aspergillus infection	30.94	19.03	24	11329	19137	79713898
Antithrombin III	30.71	19.03	6	11347	87	79732948
Escherichia bacteraemia	30.39	19.03	16	11337	6546	79726489
Kidney fibrosis	29.78	19.03	13	11340	3522	79729513
Arthralgia	29.49	19.03	23	11330	571780	79161255
Adenovirus infection	29.24	19.03	17	11336	8430	79724605
Hyperuricaemia	28.78	19.03	19	11334	11780	79721255
Infectious thyroiditis	28.75	19.03	6	11347	123	79732912
Dizziness	28.66	19.03	20	11333	526421	79206614
Cardiac pacemaker evaluation	28.39	19.03	6	11347	131	79732904
Rhodococcus infection	27.83	19.03	7	11346	335	79732700
Bacterial toxaemia	27.36	19.03	6	11347	157	79732878
Fatigue	26.75	19.03	58	11295	929669	78803366
Systemic mycosis	26.42	19.03	11	11342	2655	79730380
Weight increased	26.39	19.03	4	11349	277382	79455653
Acute respiratory failure	26.04	19.03	37	11316	59504	79673531
Graft versus host disease in skin	25.86	19.03	14	11339	6059	79726976
Mycobacterium fortuitum infection	25.56	19.03	6	11347	214	79732821
Leukopenia	25.21	19.03	53	11300	116460	79616575
Disseminated toxoplasmosis	25.20	19.03	6	11347	228	79732807
Acanthamoeba infection	25.12	19.03	7	11346	498	79732537
Product dose omission issue	24.90	19.03	3	11350	247534	79485501
Odynophagia	24.66	19.03	17	11336	11310	79721725
Blood phosphorus decreased	24.63	19.03	14	11339	6654	79726381
Genitourinary tract infection	24.02	19.03	6	11347	279	79732756
Urogenital infection bacterial	23.89	19.03	5	11348	104	79732931
Malaise	23.64	19.03	21	11332	489848	79243187
Pancreatitis acute	23.44	19.03	32	11321	49572	79683463
Candida infection	23.34	19.03	28	11325	38186	79694849
Septic shock	23.32	19.03	53	11300	122748	79610287
Encephalitis cytomegalovirus	23.28	19.03	8	11345	1142	79731893
Aplasia	22.57	19.03	14	11339	7806	79725229
Staphylococcal infection	22.28	19.03	34	11319	58261	79674774
Bronchopulmonary aspergillosis	21.87	19.03	21	11332	22273	79710762
Bronchospasm	21.75	19.03	22	11331	24837	79708198
Ectropion	21.60	19.03	6	11347	422	79732613
Parvovirus B19 infection	21.31	19.03	8	11345	1472	79731563
Cytomegalovirus gastroenteritis	21.12	19.03	6	11347	458	79732577
Abdominal discomfort	20.91	19.03	5	11348	250722	79482313
Purpura non-thrombocytopenic	20.49	19.03	5	11348	211	79732824
B-cell aplasia	20.37	19.03	5	11348	216	79732819
Pulmonary necrosis	20.33	19.03	6	11347	524	79732511
Respiratory syncytial virus infection	20.21	19.03	14	11339	9388	79723647
Demodicidosis	20.07	19.03	5	11348	230	79732805
Myocarditis toxoplasmal	20.05	19.03	4	11349	65	79732970
Micrococcal sepsis	20.05	19.03	4	11349	65	79732970
Central nervous system lesion	19.98	19.03	16	11337	13352	79719683
Hepatocellular injury	19.96	19.03	29	11324	47564	79685471
Acute graft versus host disease	19.22	19.03	14	11339	10153	79722882
Death	19.18	19.03	32	11321	566482	79166553

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	P01CX01	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS Other agents against leishmaniasis and trypanosomiasis
FDA EPC	N0000175485	Antiprotozoal
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
MeSH PA	D014344	Trypanocidal Agents
CHEBI has role	CHEBI:36335	trypanocidal drugs
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35718	antifungal agents
CHEBI has role	CHEBI:60643	N-methyl-D-aspartate receptor antagonists
CHEBI has role	CHEBI:63673	CCR5 antagonist
CHEBI has role	CHEBI:67079	anti-inflammatory agents
CHEBI has role	CHEBI:76395	histone acetyltransferase inhibitors
CHEBI has role	CHEBI:136651	S100 calcium-binding protein B inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
African trypanosomiasis	indication	27031003	DOID:10112
Pneumocystosis jiroveci pneumonia	indication	415125002	DOID:11339
Pneumocystis Carinii Pneumonia Prevention	indication
Visceral leishmaniasis	off-label use	186803007	DOID:9146
Cutaneous leishmaniasis	off-label use	240637006	DOID:9111
Hypocalcemia	contraindication	5291005
Hyperkalemia	contraindication	14140009
Torsades de pointes	contraindication	31722008
Dehydration	contraindication	34095006
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Asthma	contraindication	195967001	DOID:2841
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Toxic nephropathy	contraindication	236514003
Hypoglycemic disorder	contraindication	237630007
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.38	Basic
pKa2	10.78	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	Ki	6.29	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN	Ki	4.89	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	Ki	5.66	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	Ki	6.33	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	Ki	5.77	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	Ki	5.87	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	Ki	6.30	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	Ki	6.66	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN	Ki	5.68	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	Ki	5.60	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	Ki	6.31	DRUG MATRIX
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN	IC50	6.10	DRUG MATRIX
Plasminogen	Enzyme	P00747	PLMN_HUMAN	IC50	5.44	CHEMBL
Trypsin-1	Enzyme	P07477	TRY1_HUMAN	Ki	5.64	CHEMBL
Coagulation factor X	Enzyme	P00742	FA10_HUMAN	IC50	4.98	CHEMBL
Suppressor of tumorigenicity 14 protein	Enzyme	Q9Y5Y6	ST14_HUMAN	Ki	5.94	CHEMBL
Protein S100-B	Cytosolic other	P04271	S100B_HUMAN	Kd	6	CHEMBL
Protein arginine N-methyltransferase 1	Enzyme	Q99873	ANM1_HUMAN	IC50	4.09	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN	IC50	4.66	CHEMBL
Amiloride-sensitive amine oxidase [copper-containing]	Enzyme	P19801	AOC1_HUMAN	Ki	6.54	CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN	IC50	5.92	CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN	IC50	6.39	CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN	IC50	5.57	CHEMBL
Solute carrier family 22 member 3	Transporter	O75751	S22A3_HUMAN	IC50	5.02	CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2A	Ion channel	Q05586 Q12879	NMDZ1_HUMAN NMDE1_HUMAN	IC50	6.14	CHEMBL
Spermidine/spermine N(1)-acetyltransferase 1	Enzyme	P21673	SAT1_HUMAN	Ki	5.70	CHEMBL
Protein-tyrosine phosphatase 4A3	Enzyme	O75365	TP4A3_HUMAN	IC50	4.27	CHEMBL
Protein tyrosine phosphatase type IVA 2	Enzyme	Q12974	TP4A2_HUMAN	IC50	6.52	CHEMBL
Protein tyrosine phosphatase type IVA 1	Enzyme	Q93096	TP4A1_HUMAN	IC50	6.52	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT	Ki	6.27	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT	IC50	5.92	CHEMBL
Glutamate NMDA receptor	Ion channel		NMDZ1_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMD3B_RAT NMD3A_RAT	IC50	5.88	CHEMBL
Acrosin	Enzyme		ACRO_PIG	Ki	5.64	CHEMBL
Protein S100-B	Unclassified		S100B_RAT	Kd	4.36	CHEMBL

External reference:

ID	Source
4019043	VUID
N0000178948	NUI
D00834	KEGG_DRUG
140-64-7	SECONDARY_CAS_RN
4019043	VANDF
4019881	VANDF
C0030863	UMLSCUI
CHEBI:45081	CHEBI
CHEMBL55	ChEMBL_ID
CHEMBL361506	ChEMBL_ID
DB00738	DRUGBANK_ID
CHEMBL935	ChEMBL_ID
D010419	MESH_DESCRIPTOR_UI
4735	PUBCHEM_CID
4167	INN_ID
6823-79-6	SECONDARY_CAS_RN
673LC5J4LQ	UNII
7994	RXNORM
2196	MMSL
5250	MMSL
7933	MMSL
d00030	MMSL
002971	NDDF
16826009	SNOMEDCT_US
31692006	SNOMEDCT_US
372699006	SNOMEDCT_US
PNT	PDB_CHEM_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pentamidine Isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	13925-515	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAMUSCULAR	ANDA	13 sections
Pentamidine Isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	13925-515	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAMUSCULAR	ANDA	13 sections
Pentamidine Isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	13925-522	INHALANT	300 mg	RESPIRATORY (INHALATION)	ANDA	21 sections
Pentamidine Isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	13925-522	INHALANT	300 mg	RESPIRATORY (INHALATION)	ANDA	21 sections
pentamidine isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-748	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAMUSCULAR	ANDA	17 sections
Pentamidine Isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	39822-3030	INHALANT	300 mg	RESPIRATORY (INHALATION)	ANDA	22 sections
PENTAMIDINE ISETHIONATE	HUMAN PRESCRIPTION DRUG LABEL	1	39822-3050	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	ANDA	24 sections
PENTAMIDINE ISETHIONATE	HUMAN PRESCRIPTION DRUG LABEL	1	39822-3050	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	ANDA	24 sections
Pentam 300	HUMAN PRESCRIPTION DRUG LABEL	1	63323-113	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAMUSCULAR	NDA	13 sections
Pentam 300	HUMAN PRESCRIPTION DRUG LABEL	1	63323-113	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAMUSCULAR	NDA	13 sections
NebuPent	Human Prescription Drug Label	1	63323-877	INHALANT	300 mg	RESPIRATORY (INHALATION)	NDA	12 sections